<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192296</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP105</org_study_id>
    <nct_id>NCT00192296</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      Phase I study to evaluate the safety and tolerability of escalating single IV doses of
      MEDI-528.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this Phase I study is to evaluate the safety and tolerability of
      escalating single IV doses of MEDI-528 administered to healthy adult volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Days 0 - 84</time_frame>
    <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Abnormal Troponin Levels</measure>
    <time_frame>Days 0, 7, 14, 21, and 28</time_frame>
    <description>Number of participants with troponin levels greater than upper limit of normal (&gt; 0.05 ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Days 0 - 84</time_frame>
    <description>Number of participants experiencing serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</measure>
    <time_frame>Days 14, 28, 42, and 84</time_frame>
    <description>Number of participants who had ADA detected at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Observed Maximum Serum Concentration (Tmax)</measure>
    <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
    <description>Tmax of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Serum Concentration (Cmax)</measure>
    <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
    <description>Cmax of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</measure>
    <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
    <description>AUC(0-t) of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</measure>
    <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
    <description>AUC(0-infinity) of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</measure>
    <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
    <description>AUC(ext) of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance (CL)</measure>
    <time_frame>Days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
    <description>CL of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>Days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
    <description>T1/2 of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Rate (Vz)</measure>
    <time_frame>Days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
    <description>Vz of MEDI-528</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MEDI-528 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-528 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-528 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-528 9 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-528 0.3 mg/kg</intervention_name>
    <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
    <arm_group_label>MEDI-528 0.3 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-528 1 mg/kg</intervention_name>
    <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
    <arm_group_label>MEDI-528 1 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-528 3 mg/kg</intervention_name>
    <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
    <arm_group_label>MEDI-528 3 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-528 9 mg/kg</intervention_name>
    <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
    <arm_group_label>MEDI-528 9 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females age 18 up to and including 49 years of age at the time of the first
             dose of study drug

          -  Weight &lt; 89 kg

          -  Written informed consent obtained from the volunteer

          -  Healthy by medical history and physical examination

          -  Sexually active females, unless surgically sterile or at least one year
             post-menopausal, must use an effective method of avoiding pregnancy (including oral,
             injectable, transdermal or implanted contraceptives, IUD, female condom, diaphragm
             with spermicide, cervical cap,abstinence, use of a condom by the sexual partner or
             sterile sexual partner) for 3 months before the first dose of study drug, and must
             agree to continue using such precautions through 84 days after their dose of study
             drug. Cessation of birth control after this point should be discussed with a
             responsible physician. Sexually active males, unless surgically sterile, must likewise
             use an effective method of birth control (condom or abstinence) and must agree to
             continue using such precautions through 84 days after their dose of study drug.

          -  Use of common over-the-counter medications such as topical corticosteroids,
             decongestants, antihistamines, analgesics, and antacids is permitted unless, in the
             opinion of the investigator, it would interfere with either the volunteer's ability to
             complete the study or interpretation of study results.

          -  Ability to complete the follow-up period of 84 days

          -  Willing to forego other forms of experimental treatment during the study period of 84
             days

        Exclusion Criteria:

          -  Acute illnesses or evidence of significant active infection, such as fever ≥38.0°C
             (100.5°F) at the start of the study

          -  Use of prescription medications, other than contraceptives, in the 28-day period
             before Study Day 0

          -  Blood donation in excess of 400 mL within 6 months of the time of entry into the study

          -  History of use of tobacco products within 3 years of Study Day 0 or history of smoking
             of &gt;10 pack-years

          -  History of immunodeficiency or receipt or current use of immunosuppressive drugs
             including systemic corticosteroids

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the Study Drug (described in the Investigator's Brochure)

          -  History of substance abuse that, in the opinion of the investigator, may compromise
             the ability of the study subject to complete the study and follow-up period

          -  Evidence of any systemic disease on physical examination

          -  Evidence of infection with hepatitis A, B, or C virus or HIV-1

          -  Receipt of immunoglobulins or blood products within 60 days of entering the study

          -  Receipt of any investigational drug therapy within 60 days of the first dose of study
             drug through Study Day 84 (use of licensed agents for indications not listed in the
             package insert is permitted)

          -  Any of the following: CBC: Hgb &lt; 12.0 gm/dL; WBC &lt; 4,000/mm3; platelet count
             &lt;125,000/mm3 (or laboratory normal values); Na, K, Cl, CO2, AST, ALT, BUN, 4-hour
             fasting glucose, amylase, lipase, creatinine, troponin &gt; upper limit of normal; other
             abnormal laboratory values in the screening panel which in the opinion of the
             principal investigator are judged to be clinically significant.

          -  Clinically significant abnormality, as determined by the investigator, on 12-lead
             electrocardiogram at the time of initial screening

          -  Elective surgery planned during the study period through Study Day 84

          -  Pregnancy (sexually active females must have a negative serum pregnancy test on the
             day of the first dose of the study drug, before dosing)

          -  Nursing mother

          -  The presence of any acute or chronic organ-specific condition or any concern, which in
             the opinion of the investigator, may interfere with the conduct or interpretation of
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon Vargas, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>October 17, 2013</results_first_submitted>
  <results_first_submitted_qc>February 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2014</results_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 24 participants provided written informed consent and participated in the study between 13Aug2004 and 12Nov2004 at one site in New Orleans, Louisiana.</recruitment_details>
      <pre_assignment_details>Eligible participants received MEDI-528 in an open-label manner.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MEDI-528 0.3 mg</title>
        </group>
        <group group_id="P2">
          <title>MEDI-528 1 mg</title>
        </group>
        <group group_id="P3">
          <title>MEDI-528 3 mg</title>
        </group>
        <group group_id="P4">
          <title>MEDI-528 9 mg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MEDI-528 0.3 mg</title>
        </group>
        <group group_id="B2">
          <title>MEDI-528 1 mg</title>
        </group>
        <group group_id="B3">
          <title>MEDI-528 3 mg</title>
        </group>
        <group group_id="B4">
          <title>MEDI-528 9 mg</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="11.1"/>
                    <measurement group_id="B2" value="29.8" spread="8.4"/>
                    <measurement group_id="B3" value="25.5" spread="8.8"/>
                    <measurement group_id="B4" value="30.5" spread="8.2"/>
                    <measurement group_id="B5" value="27.9" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
        <time_frame>Days 0 - 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
          <population>All subjects who received MEDI-528</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Abnormal Troponin Levels</title>
        <description>Number of participants with troponin levels greater than upper limit of normal (&gt; 0.05 ng/mL)</description>
        <time_frame>Days 0, 7, 14, 21, and 28</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Abnormal Troponin Levels</title>
          <description>Number of participants with troponin levels greater than upper limit of normal (&gt; 0.05 ng/mL)</description>
          <population>All subjects who received MEDI-528</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>Number of participants experiencing serious adverse events</description>
        <time_frame>Days 0 - 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>Number of participants experiencing serious adverse events</description>
          <population>All subjects who received MEDI-528</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</title>
        <description>Number of participants who had ADA detected at each time point</description>
        <time_frame>Days 14, 28, 42, and 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</title>
          <description>Number of participants who had ADA detected at each time point</description>
          <population>All subjects who received MEDI-528</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Observed Maximum Serum Concentration (Tmax)</title>
        <description>Tmax of MEDI-528</description>
        <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Observed Maximum Serum Concentration (Tmax)</title>
          <description>Tmax of MEDI-528</description>
          <population>All subjects who received MEDI-528</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.0" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="2.1"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.2" upper_limit="24.2"/>
                    <measurement group_id="O4" value="0.7" lower_limit="0.5" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Serum Concentration (Cmax)</title>
        <description>Cmax of MEDI-528</description>
        <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Serum Concentration (Cmax)</title>
          <description>Cmax of MEDI-528</description>
          <population>All subjects who received MEDI-528</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="42"/>
                    <measurement group_id="O2" value="22.2" spread="30"/>
                    <measurement group_id="O3" value="59.7" spread="25"/>
                    <measurement group_id="O4" value="231.2" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
        <description>AUC(0-t) of MEDI-528</description>
        <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
          <description>AUC(0-t) of MEDI-528</description>
          <population>All subjects who received MEDI-528</population>
          <units>Micrograms times hours per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2463.7" spread="85"/>
                    <measurement group_id="O2" value="7765.6" spread="55"/>
                    <measurement group_id="O3" value="26221.5" spread="40"/>
                    <measurement group_id="O4" value="101476.7" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
        <description>AUC(0-infinity) of MEDI-528</description>
        <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
          <description>AUC(0-infinity) of MEDI-528</description>
          <population>All subjects who received MEDI-528</population>
          <units>Microgram times hours per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3982.2" spread="67"/>
                    <measurement group_id="O2" value="10084.6" spread="50"/>
                    <measurement group_id="O3" value="30035.5" spread="40"/>
                    <measurement group_id="O4" value="112344.3" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
        <description>AUC(ext) of MEDI-528</description>
        <time_frame>Days 0 (prior to and after the end of the infusion, and at 1, 2, 4, 8, and 12 hours after the end of the infusion), 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
          <description>AUC(ext) of MEDI-528</description>
          <population>All subjects who received MEDI-528</population>
          <units>Percentage of Projected AUC</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="30"/>
                    <measurement group_id="O2" value="21.5" spread="30"/>
                    <measurement group_id="O3" value="10.5" spread="64"/>
                    <measurement group_id="O4" value="8.2" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Clearance (CL)</title>
        <description>CL of MEDI-528</description>
        <time_frame>Days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CL)</title>
          <description>CL of MEDI-528</description>
          <population>All subjects who received MEDI-528</population>
          <units>Milliter per day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.5" spread="51"/>
                    <measurement group_id="O2" value="160.1" spread="34"/>
                    <measurement group_id="O3" value="166.1" spread="31"/>
                    <measurement group_id="O4" value="154.6" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life (T1/2)</title>
        <description>T1/2 of MEDI-528</description>
        <time_frame>Days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (T1/2)</title>
          <description>T1/2 of MEDI-528</description>
          <population>All subjects who received MEDI-528</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="651.1" spread="24"/>
                    <measurement group_id="O2" value="559.1" spread="36"/>
                    <measurement group_id="O3" value="581.3" spread="21"/>
                    <measurement group_id="O4" value="594.9" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Elimination Rate (Vz)</title>
        <description>Vz of MEDI-528</description>
        <time_frame>Days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, and 84</time_frame>
        <population>All subjects who received MEDI-528</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-528 0.3 mg/kg</title>
            <description>MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI-528 1 mg/kg</title>
            <description>MEDI-528 (1 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O3">
            <title>MEDI-528 3 mg/kg</title>
            <description>MEDI-528 (3 mg/kg) administered as a single, IV dose</description>
          </group>
          <group group_id="O4">
            <title>MEDI-528 9 mg/kg</title>
            <description>MEDI-528 (9 mg/kg) administered as a single, IV dose</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Elimination Rate (Vz)</title>
          <description>Vz of MEDI-528</description>
          <population>All subjects who received MEDI-528</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="38"/>
                    <measurement group_id="O2" value="5.4" spread="30"/>
                    <measurement group_id="O3" value="5.8" spread="19"/>
                    <measurement group_id="O4" value="5.5" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Days 0-84</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MEDI-528 0.3 mg</title>
        </group>
        <group group_id="E2">
          <title>MEDI-528 1 mg</title>
        </group>
        <group group_id="E3">
          <title>MEDI-528 3 mg</title>
        </group>
        <group group_id="E4">
          <title>MEDI-528 9 mg</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Parker, MD</name_or_title>
      <organization>MedImmune</organization>
      <phone>301-398-0000</phone>
      <email>parkerj@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

